Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TK1 | P04183 | 2/20 | 0.37 |
| ▸ | TK2 | O00142 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16125237 | 0.83 | TYMS (0.34) | LMNASMN1; SMN2 | |
| SCHEMBL13301604 | 0.83 | TK1 (0.34) | TK1 | |
| SCHEMBL27064734 | 0.76 | LMNA (0.43) | LMNASMN1; SMN2TK1TK2ALOX12 | |
| SCHEMBL13301602 | 0.76 | CDA (0.33) | — | |
| SCHEMBL18273921 | 0.73 | CDA (0.30) | — | |
| SCHEMBL18273920 | 0.73 | — | — | |
| SCHEMBL27056501 | 0.71 | LMNA (0.36) | LMNASMN1; SMN2TK1TK2ALOX12 | |
| SCHEMBL25505283 | 0.70 | TK1 (0.37) | LMNASMN1; SMN2TK1TK2ALOX12 | |
| SCHEMBL27102544 | 0.70 | LMNA (0.34) | LMNASMN1; SMN2TK1TK2 | |
| SCHEMBL27102578 | 0.70 | LMNA (0.34) | LMNASMN1; SMN2TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | LMNA 2720/4885SMN1; SMN2 4808/4885TK1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.